胸腺肽α1注射剂联合恩替卡韦胶囊治疗肝硬化肝功能失代偿期患者的临床疗效及安全性

Clinical efficacy and safety of thymosin alpha 1 injection combined with entecavir capsules in the treatment of patients with decompensation of liver function of liver cirrhosis

目的:探讨恩替卡韦胶囊联合胸腺肽α1注射剂对乙肝肝硬化失代偿期患者的治疗效果。方法:收治乙肝肝硬化失代偿期患者80例,分为常规组与综合组。常规组采用恩替卡韦胶囊治疗,综合组采用恩替卡韦胶囊联合胸腺肽α1注射剂治疗,比较两组治疗效果。结果:治疗后,综合组总有效率和肝功能指标均显著优于常规组(P<0.05)。结论:恩替卡韦胶囊联合胸腺肽α1注射剂对乙肝肝硬化失代偿期患者的治疗效果显著。

Objective：To explore the clinical efficacy of thymosin alpha 1 injection combined with entecavir capsules in the treatment of patients with decompensation of liver function of hepatitis B liver cirrhosis.Methods：80 patients with decompensation of liver function of hepatitis B liver cirrhosis were selected.They were divided into the conventional group and the comprehensive group.The conventional group was treated with entecavir capsules.The comprehensive group was treated with entecavir capsules combined with thymosin alpha 1 injection.We compared the therapeutic effect of the two groups.Results：After treatment,the total effective rate and liver function index of the comprehensive group were significantly better than those of the conventional group（P〈0.05）.Conclusion：The clinical efficacy of thymosin alpha 1 injection combined with entecavir capsules in the treatment of patients with decompensation of liver function of hepatitis B liver cirrhosis was significant.